Anaptysbio (ANAB) Non-cash Items (2024 - 2026)

Anaptysbio (ANAB) reported Non-cash Items of $3.9 million for Q1 2026, down 97.82% quarter-over-quarter from $180.4 million in Q4 2025.

Anaptysbio (ANAB) Non-cash Items (2024 - 2026) Analysis & Trends

Anaptysbio has reported Non-cash Items for 3 years, with the latest figure at $3.9 million in Q1 2026.

  • For the quarter ending Q1 2026, Non-cash Items changed N/A year-over-year to $3.9 million; the trailing twelve-month figure through Mar 2026 stood at $3.9 million (changed N/A YoY), and the FY2025 full-year result was $180.4 million, up 33689.14% from the prior year.
  • Non-cash Items for Q1 2026 stood at $3.9 million, down from $180.4 million in the prior quarter.
  • The five-year high for Non-cash Items was $180.4 million in Q4 2025, with the low at $534000.0 in Q4 2024.
  • Historically, Non-cash Items has averaged $61.6 million across 3 years, with a median of $3.9 million in 2026.
  • The largest YoY upside for Non-cash Items was 33689.14% in 2025 against a maximum downside of 33689.14% in 2025.
  • Anaptysbio's Non-cash Items stood at $534000.0 in 2024, then soared by 33689.14% to $180.4 million in 2025, then slumped by 97.82% to $3.9 million in 2026.
  • The last three Non-cash Items figures came in at $3.9 million (Q1 2026), $180.4 million (Q4 2025), and $534000.0 (Q4 2024), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Alterity Therapeutics 925,601.88 Bn 925,601.85 Bn -
2 Belite Bio 58,560.00 Bn 58,560.00 Bn -
3 Quantum Biopharma 17,284.41 Bn 17,284.40 Bn -
4 Legend Biotech 2,809.00 Bn 2,808.71 Bn 242.10 Mn
5 Evaxion A 1,334.43 Bn 1,334.42 Bn -
6 Akari Therapeutics 1,312.27 Bn 1,312.26 Bn -
7 Psyence Biomedical 212.16 Bn 212.16 Bn -
8 Vertex Pharmaceuticals 114.83 Bn 107.58 Bn 2.59 Bn
9 Abivax 91.96 Bn 91.96 Bn -
10 Anaptysbio 1.66 Bn 1.38 Bn -

Historic Data

Download Data
DateValue
Mar 31, 2026 3.93 Mn
Mar 31, 2026 3.93 Mn
Dec 31, 2025 180.43 Mn
Dec 31, 2025 180.43 Mn
Dec 31, 2024 534,000.00
Dec 31, 2024 534,000.00